Sanctuary Advisors LLC Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sanctuary Advisors LLC bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,663 shares of the medical research company's stock, valued at approximately $735,000.

A number of other large investors also recently made changes to their positions in BIO. Wahed Invest LLC boosted its holdings in Bio-Rad Laboratories by 14.0% in the 1st quarter. Wahed Invest LLC now owns 399 shares of the medical research company's stock valued at $138,000 after purchasing an additional 49 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its stake in Bio-Rad Laboratories by 7.7% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company's stock worth $289,000 after acquiring an additional 60 shares during the period. Capital Advisors Ltd. LLC raised its holdings in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after acquiring an additional 62 shares in the last quarter. Natixis lifted its position in shares of Bio-Rad Laboratories by 3.4% during the 1st quarter. Natixis now owns 1,986 shares of the medical research company's stock valued at $687,000 after acquiring an additional 65 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Bio-Rad Laboratories by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 27,055 shares of the medical research company's stock worth $9,358,000 after purchasing an additional 78 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

BIO has been the subject of several recent analyst reports. StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Thursday, August 1st. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price objective on the stock. Citigroup upgraded shares of Bio-Rad Laboratories from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $350.00 to $400.00 in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $401.00 target price on shares of Bio-Rad Laboratories in a report on Friday, August 16th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $368.20.

Insider Activity

In related news, COO Andrew J. Last sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP James Barry sold 623 shares of the firm's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company's stock, valued at approximately $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.06% of the company's stock.

Bio-Rad Laboratories Price Performance

NYSE:BIO traded up $4.82 on Monday, hitting $341.74. The company had a trading volume of 151,904 shares, compared to its average volume of 251,949. Bio-Rad Laboratories, Inc. has a 52 week low of $261.59 and a 52 week high of $364.24. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $9.75 billion, a price-to-earnings ratio of -32.99 and a beta of 0.95. The firm has a 50 day moving average of $329.11 and a two-hundred day moving average of $306.85.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.99. The company had revenue of $638.50 million during the quarter, compared to analysts' expectations of $645.79 million. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. Bio-Rad Laboratories's revenue was down 6.3% compared to the same quarter last year. During the same period in the prior year, the company earned $3.00 EPS. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.